ONUREG® (azacitidine) for Acute Myeloid Leukemia (AML)

FOR ADULT PATIENTS. It is not known if ONUREG^® is safe and effective in children under 18 years of age.

ONUREG^® is the first FDA-approved continued treatment for people with AML who are in first remission

ONUREG^® is a prescription medicine used for continued treatment of adults with acute myeloid leukemia (AML) who:

had a first complete remission (CR) following intensive induction chemotherapy with or without recovery of your blood cell counts, and
who are not able to complete intensive curative therapy.

It is not known if ONUREG^® is safe and effective in children under 18 years of age.

Bristol-Myers Squibb Company values your privacy. Bristol-Myers Squibb Company, its affiliates, and its agents will not sell or rent your personal information. By providing your information, you acknowledge that you have read and agree to the Bristol-Myers Squibb Company Privacy Policy.

*Required Field
First name*
Last name*
Email*
Address line
City
ZIP code*
Phone
Specialty*

ONUREG® is the first FDA-approved continued treatment for people with AML who are in first remission

Please choose an option:

ONUREG^® is the first FDA-approved continued treatment for people with AML who are in first remission